跳转至内容
Merck

Y0000639

2-氯-2′-脱氧腺苷

European Pharmacopoeia (EP) Reference Standard

别名:

2-Chloro-2′-deoxyadenosine, CdA, Cladribine

登录查看公司和协议定价

选择尺寸

100 MG
$225.00

$225.00


预计发货时间2025年5月06日详情


获取大包装报价

选择尺寸

变更视图
100 MG
$225.00

About This Item

经验公式(希尔记法):
C10H12ClN5O3
CAS号:
分子量:
285.69
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

$225.00


预计发货时间2025年5月06日详情


获取大包装报价

等级

pharmaceutical primary standard

API类

cladribine

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

−20°C

SMILES字符串

Nc1nc(Cl)nc2n(cnc12)[C@H]3C[C@H](O)[C@@H](CO)O3

InChI

1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1

InChI key

PTOAARAWEBMLNO-KVQBGUIXSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Cladribine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Skull and crossbonesHealth hazard

警示用语:

Danger

危险分类

Acute Tox. 3 Oral - Muta. 2 - Repr. 2 - STOT RE 1

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Darren S Sigal et al.
Blood, 116(16), 2884-2896 (2010-07-17)
Before the contemporary development of rationally designed antineoplastic therapies, cladribine was identified as a lymphocyte-specific agent. Its profound impact on the natural history of hairy cell leukemia, with responses approaching 100% and a median duration of response of nearly a
Clemens Warnke et al.
Clinical immunology (Orlando, Fla.), 142(1), 68-75 (2011-07-08)
There is an unmet need for more potent and convenient drugs in the treatment of patients diagnosed with multiple sclerosis (MS). Among five currently investigated oral drugs with an ongoing or completed phase III program, promising efficacy data for oral
E Van Den Neste et al.
Leukemia & lymphoma, 40(5-6), 541-550 (2001-06-28)
The purine nucleoside analogs fludarabine and 2-chloro-2'-deoxyadenosine display substantial activity in the treatment of various chronic lymphoproliferative disorders. Their major toxicities are primarily immunosuppression and myelosuppression. The profound influence of these drugs on the immune system has raised questions as
Victoria J Muir et al.
CNS drugs, 25(3), 239-249 (2011-02-18)
Cladribine, an immunosuppressant that selectively reduces peripheral lymphocyte levels, has potential as an oral therapy for relapsing-remitting multiple sclerosis. An oral (tablet) formulation is being investigated in clinical trials. In the large, well designed, phase III CLARITY trial, short-course treatment
S Schmidt
Der Nervenarzt, 81(10), 1231-1241 (2010-06-23)
Azathioprine (AZA) is a purine analogue which has been used in the treatment of multiple sclerosis (MS) for over 30 years. After the approval of immunomodulatory drugs, such as recombinant interferon beta and glatiramer acetate, AZA now only plays a

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持